How do you choose between adjuvant PCV vs temozolomide in high risk oligodendroglioma with IDH mutation and 1p/19q co deletion?

Topics: Neuro-Oncology • Medical Oncology • Neurology

NCCN lists PCV as category 1 (and now with analysis in Abstract 2002 from ASCO 2019 showing benefit in IDH mutated), and temozolomide as 2B, yet temozolomide is commonly used in practice.

Answer from: Medical Oncologist at Academic Institution

In our practice, we typically offer procarbazine/lomustine (with or without vincristine) to all patients with high risk oligodendroglioma, IDH mutated, 1p/19q codeleted. Temozolomide based on the Stupp regimen is used as an alternative when there are specific concerns for PCV related toxicity or str...

Comments

Radiation Oncologist at Center for Neurosciences
@Sani H. Kizilbash - Thank you for this reply. Do ...

Medical Oncologist at Mayo Clinic
Not yet. Accrual is still incomplete. So, CODEL is...

Related Questions